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ABSTRACT
Traditional risk factors for atherosclerotic cardiovascular
disease (CVD) do not adequately explain the considerable
increase in cardiovascular mortality observed among patients
with end-stage renal disease (ESRD): these patients experience
mortality rates 10–100 times thosewithoutESRD.Disorders of
mineral metabolism, including abnormalities in calcium,
phosphorus, parathyroid hormone, and vitamin D, represent
cardiovascular risk factors unique to the ESRD population.
These disturbances manifest clinically through the promotion
of extraskeletal calcification and disorders of bone remodeling,
two processes which appear to share a common pathogenesis.
This article presents evidence describing the impact of calcifi-
cation-induced arterial stiffness on cardiovascular outcomes of
patients with ESRD, along with data relating altered mineral
metabolism to all-cause and cardiovascular mortality. Specific
management recommendations include 1) early intervention to
prevent the development of overt secondary hyperparathyroid-
ism, 2) amore judicious strategy for vitaminD therapy, and 3) a
thoughtful approach to the use of calcium-containing phos-
phate binders, taking into account the underlying bone
remodeling disorder and the presence or absence of extraskel-
etal calcium accumulation.
Traditional risk factors for atherosclerotic cardiovas-
cular disease (CVD) do not adequately explain the
considerable increase in cardiovascular mortality
observed among patients with end-stage renal disease
(ESRD): these patients experiencemortality rates 10–100
times those without ESRD (1,2). Speculation exists
regardinguremia-specific atherogenic risk factors suchas
chronic inflammation, oxidant stress, hyperhomocyste-
inemia, and a unique dyslipidemic profile, yet there is no
consensus that chronic kidney disease (CKD) by itself
represents a state of accelerated atherogenesis (3). While
short-term cardiovascular risk in the general population
is estimated from diagnostic testing that detects ‘‘signi-
ficant’’ intraluminal stenosis of large epicardial coronary
arteries, this strategy fails to explain cardiovascular
outcomes in patients with CKD. In a prospective
evaluation of 433 incident ESRD patients, Foley et al.
(4) found no association between known coronary artery
disease (CAD)and subsequentmortality.A recent report
found that patients with ESRD and CKD with normal
coronary angiograms had 2-year hazard ratios of
mortality of 2.64 and 5.19 relative to those with normal
kidney function. These values were nearly identical to
those found in patients with ‘‘significant’’ obstructive
luminal coronary disease (4,5).
As depicted in Fig. 1, disorders of mineral metabolism
(including abnormalities in calcium, phosphorus, para-
thyroid hormone [PTH], and vitamin D) represent
cardiovascular risk factors unique to patients with
CKD. The effects of disturbed mineral homeostasis are
thought tobemediatedby thepromotionof vascular and
visceral calcification, disorders of bone remodeling, and
direct toxicity of PTH. These abnormalities affect the
cushioning/capacitance function of the arterial system
rather than the conduit function.While this consequence
is less familiar to most nephrologists, evidence now
implicates abnormalities in arterial stiffness as an
important mediator of cardiovascular events in patients
withCKD.The evolvingdiscovery of a close relationship
between bone remodeling disorders and arterial vascular
disease provides a fundamental basis for the enhanced
cardiovascular event rates seen in the CKD population,
the majority of whom have skeletal abnormalities.
Furthermore, there is accumulating evidence that the
modern management of renal osteodystrophy (ROD)
and mineral metabolism disorders may have a negative
impact on overall vascular health. This brief review is
limitedprimarily to disorders of calciumandphosphorus
homeostasis; the reader is referred to a recent review by
Rostand and Drueke (6) for a detailed discussion of the
cardiovascular toxicity of PTH and vitamin D.
Mechanisms and Basic Principles
The development of vascular calcification (VC) is a
complex, actively regulated process involving mechanisms
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similar to those of normal skeletal mineralization (7,8).
Most importantly, serum phosphate concentration is a
potent stimulator of the process of vascular calcification
(9–11). Increasing phosphate concentration in vascular
smooth muscle cell culture results in a dose-dependent
increase in intracellular phosphate via a type III sodium-
phosphate cotransporter. This ultimately increases bone-
related protein expression of markers such as cbfa-1 and
osteocalcin. Animal models confirm this phenotypic
change in vascular smooth muscle cells and human
pathologic studies in ESRD patients substantiate the
expression of bone-related proteins in areas of VC
(12,13).
Vascular calcification occurs either in the intimal or
medial vascular space. Intimal calcification develops in
concert with atherosclerotic plaque and it is now well
accepted that increasing amounts of vascular calcium in
nondiabetic, nonrenal failure patients is a surrogate for
atherosclerotic plaque burden. Diabetic and CKD
patients also accumulate calcium in the vascular media,
an event which does not impact the conduit function of
blood vessels and is not associated with plaque. Because
there is no associated impairment of distal blood flow,
the development of medial calcification has historically
generated little interest; however, the hemodynamic
consequences of medial calcification have been recog-
nized more andmore. Guerin et al. (14) have shown that
for ESRD patients, the presence and extent of VC
assessed by Doppler ultrasound predicts an increased
arterial stiffness measured either by aortic pulse wave
velocity (PWV) or carotid incremental elastic modulus
(Einc). This effect is independent of age and hypertension.
Both aortic PWV and Einc are strong independent
predictors of all-cause and cardiovascular mortality in
patients with ESRD (15). In a cohort of 241 hemodi-
alysis (HD) patients, for each 1 m/sec increase in aortic
PWV, the all-cause mortality adjusted odds ratio was
1.39 (confidence interval [CI] 1.19–1.62) (16). The
mechanism underlying this higher cardiovascular risk
appears to be a direct effect of arterial stiffness in
increasing systolic blood pressure, decreasing diastolic
blood pressure, and thus widening pulse pressure (PP).
This effectively increases left ventricular (LV) afterload
and results in left ventricular hypertrophy (LVH) (17).
By accelerating the aortic PWV, increased arterial
stiffness also results in a reflected pressure wave that
returns to the heart during systole rather than during
early diastole as occurs in subjects with normal arterial
structure. This phenomenon is well demonstrated from a
study by Asmar et al. (18) on aging (Fig. 2). This early
wave reflection further augments systolic blood pressure,
lowers diastolic blood pressure, and increases PP. This
second peak in the arterial waveform systolic blood
pressure is expressed as the augmentation index and has
been correlated with LV size in patients on HD (19–21).
Ultimately these phenomena decrease coronary perfu-
sion and result in diminished subendocardial blood flow,
particularly in patients with coexisting classic athero-
sclerotic coronary disease.
Two large and recently reported studies confirm the
adverse risk associated with high systolic blood pressure,
low diastolic blood pressure, and widened PP. Each 10
mmHg increase inPPwas associatedwitha 12%increase
in the hazard for 1-year mortality in a study by Klassen
et al. (22) involving 37,000 HD patients. Tozawa et al.
(23) analyzed 1243 Japanese HD patients and found PP
to be a more potent predictor of total mortality than
systolic or diastolic blood pressure. This effect was not
seen in diabetics; however, the PP in diabetics was
significantly higher than in nondiabetics (82 versus 68,
p < 0.0001) and likely confounded the relationship.
Interest in the detection of VC has increased with the
advent of electron beam computed tomography
(EBCT). Using a beam of electrons deflected onto a
tungsten ring with real-time gating to the electrocardio-
gram (EKG), this technique is able to image coronary
arteries with limited motion artifact. Areas of more than
2–3 pixels consistent with calcium are counted, multi-
plied by a density coefficient, and an Agatston total
calcium score is generated for the area of interest. A
complete cardiac scan takes one to two breath holds and
is complete in 1–2 minutes.
Data from the non-CKDgeneral population confirms
the ability of EBCT calcium score percentile to predict
hard coronary events (myocardial infarction [MI] or
death) with improved ROC characteristics beyond
Framingham risk factors (24). Regardless of whether
localized calcium accumulation stabilizes or destabilizes
plaque (a controversial issue), increasing total calcium
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Fig. 2. Arterial stiffness, pulsewave velocity, andwave reflections.
Pressure waves in young and old subjects. Pressure wave (——),
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Fig. 1. Interactions of calcium phosphate metabolism with car-
diovascular disease in patients with CKD.
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scores reflect an increased plaque burden, which trans-
lates into increased cardiovascular risk.
This technique cannot discriminate intimal from
medial calcium accumulation, so direct extrapolation
of EBCT results from the general population to patients
with ESRD is not possible. It is known that patients with
ESRD are more likely to have calcified atherosclerotic
plaques compared to controls; however, the EBCT
calcium score may also reflect increased medial calcium
(25). Blacher et al. (15) confirmed the significance of
arterial calcification and arterial stiffness in HD patients
by showing a striking correlation between the number of
calcified vessels and all-cause and cardiovascular mor-
tality. In this multivariate analysis, increases in common
carotid arteryEinc conferred additional risk of mortality.
It is biologically plausible that increased coronary artery
medial calcificationmay augment the risk of atheroscler-
otic disease by limiting the normal coronary remodeling
process. This could partially explain the phenomenon of
ischemic events in patients with non-‘‘significant’’ cor-
onary artery disease.
We investigated the presence of VC at the initiation of
HD using EBCT, and found that 17% of patients have
severe coronary calcification, 30% have severe aortic
calcification, and 40% have no evidence of coronary
calcification (26). Furthermore, we have shown in this
study a median coronary calcium score of 31 in new
dialysis patients. This is in stark contrast to the median
score of 595 reported by Raggi et al. (27) in patients
prevalent on dialysis for 37 months, in whom only 17%
of patients had zero coronary scores. These investigators
report a strong correlationbetween thebaseline coronary
calcium score and the presence of atherosclerotic vascu-
lar disease events.
Together these data suggest that the presence of VC
reflects a pathologic state of altered vascular structure
that has profound effects on vascular function—and
ultimately on survival. This information provides the
basis upon which it is possible to interpret clinical trials
relating abnormalities in mineral metabolism to adverse
cardiovascular events. Increased arterial stiffness, as
manifest by aortic PWV or Einc, and the presence and
extent of coronary and extracoronary vascular calcium
accumulation appear to be excellent surrogate markers
of cardiovascular outcome.
Prevalence of Disordered Mineral Metabolism
The development of increased arterial stiffness occurs
as glomerular filtration rate (GFR) diminishes and the
rate at which VC progresses is remarkably high after the
initiation of renal replacement therapy. These arterial
structural abnormalities appear to begin before patients
with CKD develop ESRD. An inverse correlation exists
between aortic PWV and estimated creatinine clearance
for patients in the lower tertile of creatinine clearance in
the general population independent of gender, mean
blood pressure, and classic cardiovascular risk factors
(28). Konings et al. (29) found a significant increase in
arterial stiffness in patients with CKD by assessing
carotid artery distensibility. These structural changes
parallel the evolution of abnormalities in mineral
metabolism as GFR declines.
Early in the course of CKD, a diminution of
1,25-vitamin D3 formation occurs and results in a
compensatory increase in PTH. Serum phosphorus
concentration begins to increase, and even small
increases within the normal range may further increase
PTH. Kates et al. (30) reported that 45% of patients
with a serum creatinine of 1.2–3.0 mg/dl had PTH
levels of 150–380 pg/ml, which was directly correlated
with a phosphorus concentration of 3.7–5.0 mg/dl. A
compensated state of mildly increased phosphorus
concentration, normal serum calcium concentration,
low-normal vitamin D3, and mild to moderately
increased PTH exists until GFR declines more
substantially. Despite the ‘‘normal’’ phosphate values,
Felsenfeld and Rodriquez (31) suggested that the
insufficient phosphate lowering effect of increased PTH
in CKD contributes to the PTH resistance and
diminishes the calcemic response of bone to PTH.
As GFR approaches stage 5 CKD, increases in
phosphorus concentration and decreases in vitamin D3
ultimately result in overt secondary hyperparathyroid-
ism in themajority of patients. Contrary to conventional
teaching, it is rare for clinically significant decreases in
albumin-adjusted serum calcium below 8.5 mg/dl to
occur. In an evaluation of 157 CKD patients, Martinez
et al. (32) found no decline in serum calcium as GFR
decreases, though only 18 patients had a GFR less than
30 cc/min. The Kidney Disease Outcomes and Quality
Initiative (KDOQI) guidelines (33) on CKD summarize
the literature regarding the prevalence of disordered
mineral metabolism in CKD (Table 1). An analysis of
practice patterns of nephrologists in patients with CKD
in the northeastern United States reveals that 55% of
patients with CKD had evidence of disturbed mineral
metabolism (phosphorus > 4.5 mg/dl or PTH > 100
pg/ml) (34).
Data from the U.S. Renal Data System (USRDS)
Dialysis Morbidity and Mortality Wave II Study of
incident HD patients in 1996 and 1997 show a mean
calcium of 8.7 mg/dl and phosphate of 5.5 mg/dl (29). In
an earlier cohort of prevalent HD patients (1990 and
1993) (30), we foundmean serumcalciumandphosphate
values of 9.4 and 6.2 mg/dl, respectively. In our analysis,
39% of patients had a mean phosphorus concentration
TABLE 1. KDOQI Guidelines: Abnormal Mineral Metabolism in CKD
d Onset and severity of bone disease and abnormal mineral metabolism are related to level of GFR with a threshold of 60 ml/min/1.73m2
d PTH levels are earliest marker of abnormal bone mineral metabolism
d Serum calcium is frequently but not consistently abnormal with decreased GFR
d Serum phosphorus is increased in patients with decreased GFR
d Bone histology is abnormal in the majority of patients with kidney failure
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greater than 6.5mg/dl, while a recent report fromESRD
Network 11 found 32% of HD patients with a mean
serum phosphorus greater than 6.0 mg/dl during a
3-month period (35). Vitamin D use was associated with
a 14% incidence of calcium · phosphate product greater
than 70, driven mainly by hyperphosphatemia, which
was found in nearly one-third of vitamin D-treated
patients. Disturbingly, patients were as likely to have
their vitamin D increased in the setting of hyperphos-
phatemia as they were to have the dose reduced or held.
Of those prescribed vitamin D, 29% had PTH values
within a target of 130–260; 33% were above this value
and 40% had PTH values below the target range. These
‘‘iatrogenic’’ disorders of mineral metabolism are likely
to have important cardiovascular consequences in
addition to the induction of low-turnover bone disease.
The complex relationship that exists betweendisorders
of bone remodeling, abnormal mineral metabolism,
vascular calcification, and the current treatment para-
digm involving phosphorus binders and vitaminD use is
shown in Fig. 3. It has become clear that the conse-
quences ofROD involvemore than an impact on skeletal
structure and function. In fact, the most significant
consequence of ROD may be the key role that bone
integrity plays inmodulating vascular health. Both high-
and low-turnover bone diseases have been associated
with elevated calciumandphosphorus andare associated
with the presence of vascular calcification and increased
mortality (36). As a result, relying solely on serum intact
PTH as a guide in decisions regarding the provision or
withholding of vitamin D may augment cardiovascular
risk, given the reported poor ability of this test to
precisely predict bone histopathology (37). New
1-84-specific PTH assays are now available, which may
improve the ability to predict bone turnover; however,
until prospective studies are completed, the role of these
new assays in clinical practice remains unclear.
Disorders of bone remodeling do not only reflect the
relative status of PTH homeostasis. Systemic and local
factors such as growth factors and local cytokine
production clearly impact bone turnover independent
of PTH and thus may influence cardiovascular risk
(38,39). Indeed, even in nonuremic patients, a strong
correlation exists between osteoporosis and vascular
calcification. Several HMG-CoA reductase inhibitors
and all bisphosphonates appear to modulate both bone
resorption and the propensity toward arterial calcifica-
tion (40). Ibandronate appears to be the most potent
inhibitor of bone resorption and arterial calcification
(41). These data suggest that the link between bone
remodeling disorders and arterial calcification is more
than biochemical, but rather is a result of a common
pathogenesis. Furthermore, it would appear reasonable
to evaluate the impact of these inhibitors of bone
resorption on renal osteodystrophy and cardiovascular
events in the CKD population (42).
Phosphorus
Phosphorus is directly involved in the pathogenesis of
VC, as described above, and is likely to be the singlemost
important modifiable risk factor in mineral metabolism
disorder-induced cardiovascular disease. Three large,
independent studies show phosphorus concentration to
be an independent predictor of mortality in ESRD. In
1998 we reported a 6% increase in mortality per 1 mg/dl
increase in serum phosphorus concentration (43). Simi-
larly Klassen et al. (22) recently found that phosphorus
concentration was directly associated with PP and that
1-year mortality was 8% higher per 1 mg/dl increase in
phosphorus concentration. In the latter analysis of
37,000 patients on HD, phosphorus concentration was
directly associated with pulse pressure, which was a
strong predictor of 1-year mortality. PP and increased
phosphorus concentration were also associated with the
development of LVH and LV dilatation in an analysis of
433 incident dialysis patients, both of which were
predictive of increased 2-year mortality (4). Preliminary
analysis of data from theDialysisOutcomes andPractice
Patterns Study (DOPPS) shows a 5% increase in the
adjusted risk of mortality per 1 mg/dl increase in
phosphorus concentration. Thus numerous data sources
confirm that as phosphorus concentration rises above
normal limits, mortality is increased.
The effect of phosphorus concentration on vascular
calcification is supported by Raggi et al. (27), who found
that the extent of EBCT-detected coronary artery
calcification in adult HD patients was associated with
age, male sex, white race, diabetes, dialysis therapy,
higher serum calcium, and higher serum phosphorus
concentration. Each 1 mg/dl increase in phosphorus
concentration conferred a risk for increased calcification
equal to 2.5 years of dialysis therapy. Serum phosphorus
concentration was also strongly correlated with aortic
calcification, as were age, race, dialysis therapy, and
PTH. Serum phosphorus concentration was higher in
young HD patients with coronary calcification than in
those without calcification, andwas positively correlated
with changes in coronary calcium scores with serial
EBCT (44). A 41% increase in relative risk of death
resulting from coronary artery disease has been reported
in patients with serum phosphate greater than 6.5mg/dl,
as has a 20% increase in mortality from sudden death
(45). In a recent examination of 12,000 ESRD patients,
control of serum phosphate was one of only four
modifiable factors significantly associated with long-
term survival, the others being dialysis dose, hematocrit,
and not missing treatments (46). These data support the
Vitamin D
High Turnover Bone Disease
High PTH















Fig. 3. Cardiovascular risks associated with vitamin D and
calcium-based phosphate binder therapy.
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cardiovascular nature of phosphorus-induced mortality
risk.
Calcium and Calcium Load
A direct association of serum calcium concentration
with CVD is less evident than that of phosphorus
concentration and is confounded by the frequent but
transient elevations in calcium concentration so com-
mon among patients with ESRD. Foley et al. (47)
reported an increase in mortality associated with
hypocalcemia less than 8.8 mg/dl; however, no data
on PTH were available to eliminate the possibility that
the risk seen reflected underlying PTH status. Chertow
et al. (48) found the opposite result in a very large
cross-sectional analysis of HD patients in whom serum
calcium concentration less than 8.0 was associated
with improved survival. We were unable to show any
significant relationship between serum calcium and
survival in an analysis of 2600 prevalent HD patients
(30), while Klassen et al. (22) report a 16% increase in
1-year mortality with each 1 mg/dl percentage increase
in serum calcium in an analysis of 37,000 HD patients.
Furthermore, serum calcium, like serum phosphorus
concentration, was associated with an increased PP,
albeit weakly. Goodman (44) reported no difference in
serum calcium between young dialysis patients with or
without coronary calcification; however, Raggi et al.
(27) found that serum calcium was strongly associated
with baseline coronary but not aortic calcium scores in
adult HD patients. Each 1 mg/dl increase in serum
calcium was associated with a risk for coronary
calcification equivalent to 5 years of dialysis therapy.
It is important to consider that serum calcium
values do not necessarily reflect calcium balance and it
is apparent that many patients with ESRD will be in
markedly positive calcium balance with the adminis-
tration of calcium-containing phosphate binders, par-
ticularly when given in combination with exogenous
vitamin D. This calcium load may itself suppress PTH,
thereby increasing the risk of low bone turnover; it has
also been clearly associated with an increased risk of
episodic hypercalcemia when compared to noncalcium-
containing phosphate binders (49). The administration
and the prescribed dose level of calcium-containing
phosphate binders has also been associated with the
presence of coronary and extracoronary vascular
calcification (14,44). In addition, a recent randomized
prospective trial in 200 prevalent HD patients demon-
strated that calcium binder administration was associ-
ated with significant progression of both coronary and
aortic calcium scores in a 1-year period, while the use
of the noncalcium binder, sevelamer hydrochloride,
was found to arrest the progression of vascular
calcification (50). This report is of interest in that
serum phosphorus and calcium concentrations and
calcium · phosphate product were aggressively con-
trolled to an equivalent degree with both study groups;
however, patients in the calcium arm were more likely
to have oversuppressed PTH and had a marked
increase in the incidence of hypercalcemia (43% versus
17% in the sevelamer arm).
Calcium · Phosphate Product
It has long been accepted that an increased cal-
cium · phosphate product augments the risk of visceral
and vascular calcification. The more clinically relevant
question is at what product level does the risk increase
and whether the risk is independent of calcium and
phosphorus concentrations.With a new appreciation for
themolecular basis for extraskeletal calcification, the risk
of an elevated calcium · phosphate product value may
vary by the specific component, though this hypothesis
has not been specifically investigated. Further confound-
ing the role of calcium · phosphate product is the
question of whether transient elevations are more or less
predictive of risk compared to sustained values above a
threshold. Many reports that find no relationship
between calcium · phosphate product and cardiovascu-
lar events are limited by the short windowof observation
regarding control of divalent ion concentrations.
We have reported an increased relative risk (RR) of
death associated with an elevated calcium · phosphate
product that reached statistical significance in the top
quintile (calcium · phosphate product greater than 72,
RR 1.34), and this was independent of PTH. A strong
relationship between calcium · phosphate product and
the RR of death from coronary artery disease (RR 1.06)
and sudden death (RR1.07) per each 10mg2/dl2 increase
was recently described; however, this seemed to be
primarily related to phosphorus concentration since
adjustment for serum phosphorus concentration made
these risks statistically insignificant (45). In a study of
young HD patients, a higher calcium · phosphate
product (mean 65mg2/dl2) was associated with coronary
calcification and also was positively correlated with
increases in coronary artery calcium score on follow-up
EBCT scans (44).
Progression of aortic calcification may also be asso-
ciated with an elevated calcium · phosphate product,
with as few as four episodes of a calcium · phosphate
product level greater than 60 mg2/dl2 in 1 year being
associated with an increased degree of aortosclerosis,
particularly in diabetic HD patients (51). This aortic
calcification is related to arterial stiffness as measured by
aortic PWV (52).
Management
Initial management of incipient secondary hyper-
parathyroidism should attempt to prevent parathyroid
hyperplasia by controlling serum phosphorus concen-
tration through dietary phosphate restriction and the
use of calcium-containing binders. The provision of
calcium binders is unlikely to be of any harm in
patients with preserved skeletal integrity and early
stages of CKD, and may ameliorate hypocalcemia in
those patients in whom it exists. The goal phosphorus
concentration in this stage should be less than 4.5 mg/
dl. If control of phosphorus concentration through
calcium binder therapy is inadequate to maintain PTH
within normal limits, oral vitamin D3 in doses less
than 0.5 lg/day has been shown to be safe and
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effective, with no observed impact on residual renal
function (53,54). However, serum calcium and phos-
phorus values must be closely followed if vitamin D
compounds are prescribed.
As patients develop stage 5 CKD, control of
calcium, phosphorus, and PTH becomes more diffi-
cult. Dietary restriction of phosphorus has limited
effectiveness and is undesirable if it decreases protein
intake as it may result in protein malnutrition.
Indeed, serum phosphorus concentration and PTH
are directly related to the nutritional status of elderly
HD patients (55). KDOQI guidelines, which recom-
mend 1.2 g/kg/day protein intake in patients with
ESRD, obligate typically more than 1000 mg/day of
phosphorus. In this setting, available data demand
that calcium-based phosphate binders must be limited
in order to lessen the risks of calcium loading,
hypercalcemia, elevated calcium · phosphate product,
oversuppression of PTH, and progression of vascular
calcification. It is unclear what the ‘‘safe’’ dose of
calcium may be and it almost certainly varies with the
underlying bone disorder and whether or not vascular
calcification already exists. In the setting of low-
turnover bone disease or known calcification, calcium
should be severely limited in favor of nonaluminum,
noncalcium phosphate binders.
The goal of binder therapy should be a normal serum
phosphorus concentration less than 5.5 mg/dl without
hypercalcemia (less than 10 mg/dl) or excessive calcium
loading. Previously accepted standards of care (phos-
phorus concentration less than 6 mg/dl, calcium concen-
tration less than 11mg/dl, calcium · phosphate product
less than 70 mg2/dl2) must be abandoned in view of the
effect on vascular calcification and survival.
Clinical management of secondary hyperparathyroid-
ism remains quite difficult for nephrologists today.
Both excessive or inadequate PTH must be avoided;
however, given the limitations of the current assay and
its modest correlation with bone histology, one can
only say with confidence that PTH less than 100 pg/ml
or greater than 450 pg/ml are likely to be undesirable.
A major shift must occur in practice when PTH values
are between these extremes, with recognition of the
serious toxicity associated with the ability of vitamin D
therapy to produce elevations in calcium and phos-
phorus. Although calcium supplementation alone may
effectively control mild to moderate secondary hyper-
parathyroidism, the doses required to do so have been
reported to be as high as 7000 mg of elemental
calcium/day (56). Vitamin D analogues, which have
less of an effect on gastrointestinal calcium and
phosphate absorption, are preferred if vitamin D is
to be administered. The future management of
secondary hyperparathyroidism will involve the use
of calcimimetic agents, which are agonists of the
calcium-sensing receptor and have the ability to
suppress PTH secretion and parathyroid gland hyper-
plasia while avoiding the adverse effects on calcium
and phosphorus homeostasis (57,58). Furthermore, the
conceptual basis for achieving a target PTH may
change with the recognition that cyclic PTH levels
increase bone formation and bone mass (59).
We advocate a ‘‘do no harm’’ approach to PTH
managementwithin the range stated above,which acts to
balance the potential toxicity of PTH with the clear risk
associated with phosphorus and calcium elevations.
Despite thepopularmovement away frombonebiopsies,
biopsy data may be needed to appropriately balance
these risks until definitive data are available with the
newer PTH assays.
Specific therapy targeting arterial stiffness may be a
therapeutic strategy in the future. There is some evidence
that HMG-CoA reductase inhibitors and calcium
channel blockers may reduce the accumulation of
calcium in atherosclerotic plaques and recently both of
these classes of drugs have been associated with
increased survival in patients with ESRD (60–62).
Calcium channel blocker use was associated with a
32% lower RR of cardiovascular mortality among a
cohort of 4065 incident ESRD patients, an effect which
may be related to its ability to prevent PTH-induced
increases in intracellular calcium accumulation. The
renin-angiotensin-aldosterone system may also be im-
portant in the development of arterial stiffness. In a
cohort of 150 HD patients, Guerin et al. (63) have
shown that patients who had both blood pressure
lowering and a decrease in their aortic PWV had a
survival advantage, particularly with the use of the ACE
inhibitor perindopril. In addition, there is accumulating
evidence that bisphosphonates not only have a beneficial
impact on bone resorption in osteoporosis, but that they
may inhibit arterial calcification and lipid accumulation
(64). Though they continue to be dismissed in the man-
agement of renal osteodystrophy, this important class of
drugs may prove to be quite beneficial for both skeletal
and vascular integrity.
Conclusion
Disturbances in mineral metabolism affect the cardio-
vascularoutcomesofpatientswithCKD, likelymediated
by their ability to alter the cushioning/capacitance
function of arteries and to promote coronary, extracor-
onary, and visceral calcification. Interventions to ameli-
orate these effectsmust begin early in the course of CKD
when the underlying abnormalities begin. The preven-
tion of hyperphosphatemia andhypercalcemia should be
paramount when developing strategies to manage renal
osteodystrophy. An expanding understanding of the
mechanismsof bone remodeling andarterial calcification
suggest that these processes are closely linked. It may be
that the almost universal disturbances in normal bone
remodeling underlie the greatly increased cardiovascular
risk seen in patients with ESRD. Thus mineral metabo-
lism disorders should be considered as important and
unique cardiovascular risk factors in patients withCKD.
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Why ‘‘Nephrology’’?
Have you ever wondered how the specialty of Nephrology got its name, and when? Why are
we called ‘‘nephrologists’’ and not (for example) ‘‘renologists’’? Back in 1940 there was no
Nephrology – only a scarerted group of physicians and scientists in interested in studying the
kidney and its diseases world-wide. There was no dialysis, and no renal biopsies. As these
techniques were introduced into clinical medicine around 1950, and investigation of renal
physiology flowered, so Nephrology emerged at that time – but as yet had no name....
The introduction of this term is often attributed to either Gabriel Richet or Jean Hamburger, in
Paris or Kenzo Oshima in Japan in 1960. In fact, the term is much, much older. Hamburger
himself (1) found it in the French dictionaries of Boiste (1803) and Morin (1809), and most
famously in Littré’s widely used dictionary of 1862 – but only in the sense of renal anatomy. Carl
Gottshalk also identified it in an American dictionary of 1842 (Dunglison’s). The earliest use I can
find of this term outside of a dictionary, however, and in its modern sense is by the English
nephrologist Arnold Osman (1893–1972) (2). On several occasions from 1945 (3) onwards he
referred to nephrology and nephrologists, and described himself as ‘‘Honorary Nephrologist,
Children’s hospital, Hampstead’’. A 10,000 word document from 1948 in his unpublished papers
is called‘‘The science and practice of nephrology ’’ in which the terms ‘‘Nephrology’’ and
‘‘Nephrologist’’ are used throughout. In 1950, in an obituary of Franz Volhard (BMJ I: 1376, 1950)
he wrote ‘‘Volhard made many contributions to the practice of nephrology … no-one has
made more contributions to this important branch of medicine ’’, and in 1952, in a review of
Homer Smith’s great classic The kidney: structure and function ‘‘ he added ‘‘the nephrologist
and the research worker will find it indispensable ’’. (Br Med J ii: 376, 1952). Why, when he and
other British nephrologists formed the first nephrological society in 1950 (with Osman as
president) it was called the ‘‘Renal Association’’ (4) is unclear! In addition in 1954 the Italians
founded the Minerva Nefrologica, and in 1957 the Società Italiana di Nefrologia. Thus it is
certain that the word was current in the 1950s and even the 1940s, and is much older than
usually believed, even if it did not receive wide currency until it was used in the title of the first ISN
meeting in Evian in 1960. The French Société de Néphrologie was registered by Marcel Legrain,
its then president in May 1960, a few months before the ISN meeting; it had been preceded by
the Société de Pathologie Rénale, founded in 1949, the oldest body of nephrologists in the
world.
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